WeVote
Log In

Bill

Bill

SB 1355

AN ACT CONCERNING PRESCRIPTION DRUGS, DEVICES AND NONLEGEND DRUGS.

2025 Regular Session

Connecticut legislation regulating prescription drugs, medical devices, and OTC medications advances through Senate amendments toward House consideration with unclear final regulatory requirements.

BILL PASSED TEMPORARILY
#civilactions #consumerprotectiondepartment #drugs #electronicgovernmentinformation #fees #fines(penalties) #permits #pharmaceuticalindustry #pharmaceuticalmanufacturingcompanies #pharmacies #pharmacists #reports #vendingmachines #veterinarians #violations #wholesaletrade
0
WeVote Research Nonpartisan
Bill Summary · SB 1355

Legislative bill overview

SB 1355 is a Connecticut bill addressing regulation and oversight of prescription drugs, devices, and nonlegend drugs (over-the-counter medications). The bill has passed its initial legislative phases and is currently on the House calendar for consideration. The specific provisions are not detailed in the action history provided, though the amendments suggest negotiations over regulatory scope and implementation.

Why is this important

Prescription drug and medical device regulation affects medication accessibility, pricing, safety standards, and consumer protections for Connecticut residents. Changes to these regulations can influence pharmaceutical market practices, pharmacy operations, and how quickly new treatments reach patients. The bill's passage through Senate amendments indicates legislative prioritization of drug policy in the state.

Potential points of contention

  • Regulatory scope: Disagreement over which drugs and devices fall under state versus federal oversight, particularly for nonlegend drugs where federal regulation is already limited
  • Implementation costs: Whether new oversight requirements create additional burden on pharmacies, manufacturers, or state agencies without corresponding funding
  • Market access: Concerns that stricter regulations could delay patient access to medications or increase costs, versus concerns that insufficient regulation creates safety risks

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.